These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 15823633

  • 1. Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality.
    Jones M, Schenkel B, Just J.
    Int J Cardiol; 2005 Apr 20; 100(2):253-65. PubMed ID: 15823633
    [Abstract] [Full Text] [Related]

  • 2. [Cardioprotective effect of erythropoietin preparations in patients with chronic renal failure].
    Nikolaev AIu, Ermolenko VM, Milovanova LIu, Milovanov IuS.
    Ter Arkh; 2004 Apr 20; 76(9):40-3. PubMed ID: 15532375
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 20; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Left ventricular hypertrophy and heart failure in women.
    Agabiti-Rosei E, Muiesan ML.
    J Hypertens Suppl; 2002 May 20; 20(2):S34-8. PubMed ID: 12183849
    [Abstract] [Full Text] [Related]

  • 8. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E.
    J Clin Oncol; 2005 Sep 01; 23(25):5960-72. PubMed ID: 16087945
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar 01; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 01; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure.
    Singh NP, Chandrashekhar, Nair M, Anuradha S, Kohli R, Agarwal SK.
    J Assoc Physicians India; 2000 Mar 01; 48(3):301-6. PubMed ID: 11229114
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
    Rossert J, Gassmann-Mayer C, Frei D, McClellan W.
    Nephrol Dial Transplant; 2007 Mar 01; 22(3):794-800. PubMed ID: 17210593
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.